Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03949283 · ClinicalTrials.gov registry record · Phase 3
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
A Phase 3 study of Recurrent Ovarian Carcinoma and Platinum-resistant Ovarian Cancer, sponsored by Cordgenics.
- Active
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 8
- Study locations
NCT03949283: Active Phase 3 study of Recurrent Ovarian Carcinoma and Platinum-resistant Ovarian Cancer, sponsored by Cordgenics.
NCT03949283 is a Phase 3 study of Recurrent Ovarian Carcinoma and Platinum-resistant Ovarian Cancer that is active but no longer recruiting, run by Cordgenics. The registered enrollment target is 150 participants, above the 120-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (25% higher). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03949283, a Phase 3 study of Recurrent Ovarian Carcinoma and Platinum-resistant Ovarian Cancer, is active but no longer recruiting, sponsored by Cordgenics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer. Population studied will be female participants experiencing a recurrent platinum-resistant ovarian cancer (no mucinous, low grade serous, or pure sarcoma types), with ≤ 5 prior treatments, and a performance status 0-1.
Primary Outcome
Objective response rate (ORR) as measured by RECIST version 1.1 criteria in recurrent EOC patients who have had ChemoID-guided treatment versus physician choice control treatment (chemotherapy chosen by the physician from the provided list).
Conditions Studied
Interventions
- DRUG Standard Chemotherapy
- DIAGNOSTIC_TEST ChemoID Assay
Study Locations (8)
West Virginia
- Charleston Area Medical Center (CAMC) - Charleston
- Edwards Comprehensive Cancer Center - Cabell Huntington Hospital - Huntington
California
- Kaiser Permanente - Los Angeles
Florida
- Miami Cancer Institute/Baptist Health South Florida - Miami
Louisiana
- LSU Health Sciences Center - New Orleans
Ohio
- University of Cincinnati Cancer Institute - Cincinnati
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Pennsylvania
- West Penn Hospital, Allegheny Health Network - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 3 |
What the registry record for NCT03949283 still lists
NCT03949283 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 120-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (25% higher).
The record links to 2 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Standard Chemotherapy is the first listed.
NCT03949283 lists 8 locations in 7 states (West Virginia, California, Florida).
Frequently Asked Questions
What is clinical trial NCT03949283 about?
NCT03949283 is a clinical study titled "Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer". The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer. Population studied will be...
What is the current status of trial NCT03949283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2019-07-26. Estimated completion is 2024-12-30.
What conditions does trial NCT03949283 study?
This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer.
What interventions are being tested in trial NCT03949283?
The interventions under investigation include: Standard Chemotherapy (DRUG), ChemoID Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03949283?
This trial is sponsored by Cordgenics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03949283 being conducted?
This trial has 8 study locations across California, Florida, Louisiana, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03949283's enrollment target sits among peer trials
150 7th of 39 higher than 33 of 39 other Recurrent Ovarian Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
RECRUITING · Phase 2
-
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
RECRUITING · Phase 2
-
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI